Posted in | News | Business | Petrochemicals

Samsung Total Selects Basell's Spherizone Technology for a New 250 KT Polypropylene Plant

Samsung Total Petrochemicals Company Ltd. has selected Basell’s Spherizone technology for a new 250 KT per year polypropylene plant it will build at Daesan, Korea. Start-up is planned for the end of 2007.  It is the first Spherizone license in Asia and the fifth worldwide.

“We’re pleased that Samsung Total will be the first licensee of the Spherizone process in the Asia Pacific region,” said Just Jansz, president of Basell’s Technology Business, who attended a signing ceremony in Seoul, Korea.  “For half a century, Basell and its predecessors have led the evolution of the global polyolefins industry by being in the forefront of the discovery, industrial commercialization and technological development of polypropylene as well as the licensing of polypropylene technologies. This new plant represents a key milestone for Spherizone.”

The Spherizone process is Basell’s newest polypropylene technology designed around the company’s patented multi-zone circulating reactor system which can produce bi-modal products in a single reactor. Basell began licensing the technology in 2003.

Tecnimont S.p.A. of Italy has been selected to prepare the basic design package; Samsung Engineering will do the detailed engineering.

Samsung Total intends to purchase catalysts for the plant from Basell.

In addition to the new Spherizone plant, Samsung Total plans to expand its cracker, build a metathesis unit and increase styrene capacity at the Daesan site.

For more information on polypropylene, click here.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.